We are live on ! Find out more
SSC

Spruce Street Capital Portfolio holdings

AUM $510M
This Fund
S&P 500
This Quarter Est. Return
+44.39%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$416M
AUM Growth
+$113M
Cap. Flow
+$9.08M
Cap. Flow %
2.18%
Top 10 Hldgs %
65.8%
Holding
34
New
7
Increased
12
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
ANRO icon
Alto Neuroscience
ANRO
+$20.4M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$14.4M
3
CATX icon
Perspective Therapeutics
CATX
+$11.1M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$10.5M
5
RLMD icon
Relmada Therapeutics
RLMD
+$10.3M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$51.3M
2
ERAS icon
Erasca
ERAS
+$41M
3
EYPT icon
EyePoint Inc
EYPT
+$17.9M
4
OCUL icon
Ocular Therapeutix
OCUL
+$9.52M
5
PCVX icon
Vaxcyte
PCVX
+$8.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.78%
2 Financials 1.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALEC icon
26
Alector
ALEC
$219M
$4.52M 1.09%
2,101,068
+983,082
+88% +$1.97M
LONA
27
LeonaBio Inc
LONA
$74.8M
$3.84M 0.92%
393,701
– –
CRVS icon
28
Corvus Pharmaceuticals
CRVS
$1.25B
$3.39M 0.81%
+231,585
New +$3.7M
ABVX
29
Abivax
ABVX
$10.4B
– –
-49,119
Closed -$6.62M
CDTX
30
DELISTED
Cidara Therapeutics
CDTX
– –
-232,269
Closed -$51.3M
HELP
31
Cybin Inc
HELP
$743M
– –
-770,000
Closed -$6.3M
EYPT icon
32
EyePoint Inc
EYPT
$1.27B
– –
-981,543
Closed -$17.9M
OCUL icon
33
Ocular Therapeutix
OCUL
$2.2B
– –
-783,999
Closed -$9.52M
STRO icon
34
Sutro Biopharma
STRO
$340M
– –
-75,594
Closed -$875K
1
2

Similar funds

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
AGC
Aspen Grove Capital Avon, Colorado $514M AUM 21.8% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $515M AUM 36.69% 1-Year Est. Return
MCCP
Mission Creek Capital Partners San Francisco, California $501M AUM 28.4% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BFIC
Bedell Frazier Investment Counselling Walnut Creek, California $495M AUM 29.32% 1-Year Est. Return
TM
Taproot Management New York $530M AUM

Spruce Street Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Spruce Street Capital held 34 positions worth $416M, up 37% from $303M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Spruce Street Capital's Q1 2026 filing shows 7 new, 12 increased, 3 reduced and 6 closed positions. Its largest new stake was Perspective Therapeutics: 2,627,107 shares worth $11M. The largest sale was Cidara Therapeutics, an estimated $51.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

  • Spruce Street Capital's largest Q1 2026 buy was Perspective Therapeutics: 2,627,107 shares worth $11M.
  • Spruce Street Capital added most to Alto Neuroscience in Q1 2026, an estimated $20.4M increase.
  • Spruce Street Capital's biggest Q1 2026 reduction was Erasca, cutting an estimated $41M.
  • Spruce Street Capital fully exited Cidara Therapeutics in Q1 2026, selling an estimated $51.3M.
  • Spruce Street Capital's ten largest holdings make up 66% of its $416M portfolio in Q1 2026.
  • Spruce Street Capital opened 7 new positions and closed 6 in Q1 2026.
  • Spruce Street Capital's portfolio value rose 37% quarter-over-quarter to $416M.

Based on Spruce Street Capital's 13F filing for Q1 2026, filed 14 May 2026.